Genprex

Reprogramming the course of cancer

Technology

Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Pipeline

We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.

Management Team

We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

What they’re saying

In the Media


Catch up with our

Latest News


Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies

New license agreement expands Genprex’s oncology franchise

Genprex Issues April 2020 Shareholder Letter

Company provides updates on recent regulatory, clinical, operational, and business developments